MentionFox
Home › Executive changes › RenovoRx, Inc.
Leadership changes · RNXT · SEC Form 8-K, Item 5.02

Leadership changes at RenovoRx, Inc. (2026)

Before you join, sell to or invest in RenovoRx, Inc.

MentionFox check on RenovoRx, Inc.: only 2 sources on file so far (checked 14 November 2026). Run a full check before you rely on it. mentionfox.com/c/executive-changes/renovorx

Check RenovoRx, Inc. before you join, sell or invest Free, no sign-up: every record on file, each linked to its source.

What do you want to do about RenovoRx, Inc.?

Who joined and who left RenovoRx, Inc. (RNXT)? 2 appointments and 1 departure reported from 2026-02-06 to 2026-03-27, each cited to the company's own filing.

Ramtin Agah was named Chief Medical Officer of RenovoRx, Inc., effective February 27, 2026. As of November 14, 2026, RenovoRx, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from February 6, 2026 to March 27, 2026, naming 2 appointments and 1 departure (Form 8-K, March 27, 2026).

29 companies changed executives this week, 1 had other signals.

Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.

ONITY GROUP INC.announced the departure of its Chief Investment Officer
Adicet Bio, Inc.announced the departure of its Director
MAMMOTH ENERGY SERVICES, INC.announced the departure of its Chief Operating Officer
CERENOME, INC.named a new Director
Cohen & Co Inc.named a new Chief Executive Officer
Check one company free All companies that changed executives this week

Laurence Marton is also named on 3 other Form D filings ↓

Sell to companies like RenovoRx, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

Changes3
In (appointed)2
Out (departing)1
Latest filing2026-03-27

RenovoRx, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-02-06 to 2026-03-27. They name 3 people, with 2 appointments and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as RenovoRx, Inc. files it.

Also on the record for RenovoRx, Inc.

DateRecordFigureOur pageSource
November 6, 2026Stake report, Schedule 13G/A, by BOSTON SCIENTIFIC CORP—5%+ stakesSource
April 27, 2026Stake report, Schedule 13G/A, by Orin Hirschman9.8% of the class5%+ stakesSource
April 9, 2026Form D, private offering$10M soldForm D pageSource
January 30, 2026Stake report, Schedule 13G/A, by Orin Hirschman7.1% of the class5%+ stakesSource
November 13, 2025Stake report, Schedule 13G/A, by AWM Investment Company, Inc.2.4% of the class5%+ stakesSource
November 10, 2025Stake report, Schedule 13G/A, by Orin Hirschman7.1% of the class5%+ stakesSource
August 14, 2025Stake report, Schedule 13G/A, by AWM Investment Company, Inc.5.1% of the class5%+ stakesSource

Selling to them or working with them? See who runs RenovoRx, Inc. now and the warning signs.

Free to see. No signup.

Keep reading

More on RenovoRx, Inc. and the records around it.

The people at RenovoRx, Inc.

  • Laurence Marton is also named on 3 other Form D filings: Matternet, Inc. (Jun 2026)

RenovoRx, Inc. elsewhere on the record

Companies that share a holder

Want the whole picture on RenovoRx, Inc.?

Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News

A Full Report on RenovoRx, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on RenovoRx, Inc. covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    9 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

Timeline

FiledIn / outPersonRoleEffectiveSource
2026-03-27InChief Medical Officer2026-02-278-K, 2026-03-27
2026-02-06OutPrincipal Accounting Officer2026-02-038-K, 2026-02-06
2026-02-06InChief Financial Officer8-K, 2026-02-06

Why did they leave? What the filings say

RenovoRx, Inc.'s filings state no reason for the departures below. Where a filing gives none, it says so here; nothing is inferred.

Who leads RenovoRx, Inc., as last reported?

For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.

Selling to RenovoRx, Inc.?

New leaders reset buying decisions — get the Full Report on RenovoRx, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.

Get the Full Report

Watch RenovoRx, Inc. (free up to 3)

Hiring for a seat like this?

Find people with the same kind of experience as the Chief Medical Officer at RenovoRx, Inc., with the record behind each one.

Find candidates like Chief Medical Officer at RenovoRx, Inc.

Every change, in the filing's words

Filed 2026-03-27 · 8-K

Appointed: Ramtin Agah, Chief Medical Officer, effective 2026-02-27

On March 24, 2026, the board of directors (the "Board") of RenovoRx, Inc., a Delaware corporation (the "Company"), formally appointed Ramtin Agah, M.D., Chief Medical Officer and Chairman of the Board of the Company, to the newly created position of Executive Chairman, effective February 27, 2026.

Also stated in this filing

  • Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers.
  • In connection with his roles as Chief Medical Officer and Executive Chairman, Dr. Agah accepted an offer letter from the Company on the same date (the "Agah Offer Letter") to amend, restate and replace certain Consulting Agreement, dated January 1, 2018, between Dr. Agah and the Company.
  • Dr. Agah acknowledged that certain Amended and Restated Change in Control and Severance Agreement, dated November 10, 2025, between the Company and Dr. Agah, remained in full force and effect.
  • Pursuant to the Agah Offer Letter, the Company shall pay Dr. Agah annualized base salary of $450,000, based on a minimum of 30 hours worked per week, payable semi-monthly, for his employment starting as of January 1, 2026.
  • Dr. Agah will be eligible to receive an annual discretionary bonus of up to 40% of his annualized base salary, dependent on the performance of the Company and his individual performance, as determined by the Company in its discretion (the "Bonus").
  • The first Bonus shall be payable in 2027 for 2026 performance.
Filed 2026-02-06 · 8-K

Departing: Ronald B. Kocak, Principal Accounting Officer, effective 2026-02-03

On February 3, 2026, Ronald B. Kocak notified the board of directors (the "Board") of RenovoRx, Inc., a Delaware corporation (the "Company"), his intent to resign from his position as Principal Accounting Officer of the Company, effective as of the close of business on February 3, 2026.

Appointed: Mark Voll, Chief Financial Officer

On February 4, 2026, the Board appointed Mark Voll, a consultant to the Company, as the Company's Chief Financial Officer, effective immediately.

Also stated in this filing

  • Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers.
  • The circumstances of his resignation do not constitute "Good Reason" (as defined in the Amended and Restated Change in Control and Severance Agreement, dated November 10, 2025, by and between the Company and Mr. Kocak (the "Kocak Agreement")).
  • His resignation is voluntary and is not a "Qualified Termination" (as defined in the Kocak Agreement).
  • Mr. Kocak retains his position as Vice President and Controller and maintains his current salary for the year of 2026.
  • As the Chief Financial Officer, Mr. Voll shall serve in the capacity as the Company's Principal Financial and Accounting Officer for purposes of the Company's compliance with federal securities laws, rules and regulations and all other regulatory purposes.
  • In connection with his appointment, Mr. Voll entered into a Consulting Agreement with the Company on the same date (the "Voll Consulting Agreement").
  • Mr. Voll, age 72, has more than 30 years of experience in finance and accounting and has served as Chief Financial Officer for multiple public and private high-technology companies.
  • Mr. Voll served as Vice President of Business Operations and Chief Financial Officer of Achronix Semiconductor, a publicly held semiconductor company, from December 2020 to December 2021.

Tools for this story

Each opens in a new tab, filled in for RenovoRx, Inc.. With no account yet, you sign up free and land on the result.

Where this comes from

A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.

Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.

Not for employment, credit or tenancy decisions. MentionFox research is for sales, partnership and investor research. Permitted use

Cite this page

Permanent URL: https://mentionfox.com/executive-changes/renovorx
Last updated 2026-11-14
Primary record: SEC filing 1 · SEC filing 2 · SEC filing 3 · SEC filing 4
RenovoRx, Inc. executive departure 2026. MentionFox, 2026-11-14. https://mentionfox.com/executive-changes/renovorx